The AAIC.20 meeting saw the presentation of a poster covering the validation work done on salivary lactoferrin as a biomarker specific to Alzheimer´s disease.The work was led by top research groups in Madrid, including the CNIC (The National Center for Cardiovascular Research) headed up by Valentin Fuster (who also serves as Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and Director of the Zena and Michael A. Wiener Cardiovascular Institute, the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, and the Richard Gorlin, MD/Heart Research Foundation Professor at Icahn School of Medicine at Mount Sinai, New York, NY, as well as Seville and Vitoria in Spain and San Antonio, TX.

The validation showed that salivary lactoferrin seems to have a very good diagnostic performance in detecting Alzheimer´s disease. The researchers concluded that their study support the possible utility of salivary lactoferrin as a new non-invasive and cost-effective Alzheimer´s disease biomarker.

The AAIC.2020 was a virtual meeting and so we could not meet with you at this great event this year, but let’s hope we can meet up at AAIC.21 in July 2021 in Boston, MA.